Treatment strategies primarily involve blocking implicated cytokine receptors or signaling cascades, particularly IL-6 and IL-1, with agents such as tocilizumab and anakinra.94, –96 However, tocilizumab has demonstrated efficacy in managing ICANS primarily when accompanied by CRS. This evidence concerns the gene IL6 and congenital rubella syndrome.